Vital signs included systolic and diastolic blood pressure, body temperature, pulse rate (PR), respiratory rate, orthostatic blood pressure and pulse rate assessments. The markedly abnormal value (MAV) criteria for vital signs were systolic blood pressure (SBP) less than (\<) 85 millimeter of mercury (mmHg), greater than (\>) 180 mmHg; diastolic blood pressure (DBP) \<50 mmHg, \>110 mmHg; body temperature \<35.6 degree Celsius, \>37.7 degree Celsius; PR \<50 beats per minute (bpm), \>120 bpm; respiratory rate \<12 breaths per minute (breaths/minute), \>16 breaths/minute; orthostatic hypotension decrease in SBP greater than or equal to (\>=) 20 mmHg or a decrease in DBP \>=10 mmHg on standing; orthostatic tachycardia defined as an increase of \>30 bpm or heart rate (HR) \>120 bpm on standing. Number of participants who met the MAV criteria for vital signs at least once post dose were reported.

ECG included HR, PR, QT interval with Fridericia correction (QTcF) interval and QRS duration. The MAV criteria for 12-lead ECG parameters included heart rate \<50 bpm, \>120 bpm; PR interval less than or equal to (\<=)80 milliseconds (msec), \>=200 msec; QTcF interval \>=500 msec; QRS duration \<=80 msec, \>=120 msec. Number of participants who met the MAV criteria for ECG parameters at least once post dose were reported.

Clinical laboratory parameters included tests for chemistry and hematology. The MAV criteria for laboratory value included hemoglobin \<0.8\*LLN,\>1.2\*ULN; hematocrit \<0.8\*LLN,\>1.2\*ULN;RBC count \<0.8\*LLN, \>1.2\*ULN;WBC count \<0.5\*LLN, \>1.5\*ULN; platelet count \<75\*10\^9 per liter, \>600\*10\^9 per liter; ALT \>3\*ULN; AST \>3\*ULN,GGT \>3\*ULN, normal baseline; \>2\*baseline,abnormal baseline; ALP\>3\*ULN, normal baseline; \>2\*baseline, abnormal baseline; total bilirubin \>1.5\*ULN, normal baseline; \>1.5\* baseline, abnormal baseline; albumin \<25g/L; total protein \<0.8\* LLN, \>1.2\*ULN; creatinine \>177 micromole per liter; blood urea nitrogen \>10.7 mmol/L; sodium \<130 mmol/L, \>150mmol/L; potassium \<3.0mmol/L, \>5.5 mmol/L; glucose \<3mmol/L, \>10mmol/L; chloride \<75mmol/L, \>126mmol/L; calcium corrected serum calcium of \<LLN-8.0 mg/dL; \<LLN-2.0mmol/L; ionized calcium \<LLN-1.0mmol/L; bicarbonate \<8.0mmol/L. Number of participants who met the MAV criteria for laboratory value at least once post dose were reported.

A TEAE was defined as an adverse event (AE) that started or worsened after first dose of the study treatment and within 30 days of last dose of study treatment. An AE was defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it did not necessarily had to have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it was considered related to the drug.